A New Wave of Progress in the Treatment of Renal Cell Carcinoma: Highlights from ASCO GU 2023 and Beyond : Episode 4
Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
Hans Hammers, MD, PhD, explains the situations in which he would choose an ipilimumab/nivolumab treatment regimen over one of the discussed IO/TKI regimens.
EP: 1.Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)
EP: 2.Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC
EP: 3.Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER
Now Viewing
EP: 4.Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC
EP: 5.Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC
EP: 6.Treatment Approaches for Patients with RCC and Bone Metastases
EP: 7.Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment
EP: 8.Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial
EP: 9.Updates in the Adjuvant Treatment of Metastatic RCC
EP: 10.Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC
EP: 11.Preferred Treatment Regimens for Refractory RCC
EP: 12.Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC
EP: 13.Genetic Counseling for Patients with Non-Clear Cell RCC
Related Videos
Related Content
